Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Braylan, S. Atwater, L. Diamond, J. Hassett, M. Johnson, P. Kidd, C. Leith, D. Nguyen (1997)
U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data reporting.Cytometry, 30 5
Carleton Stewart, F. Behm, John Carey, Joanne Cornbleet, Ricardo Duque, S. Hudnall, Paul Hurtubise, Mike Loken, Raymond Tubbs, Susan Wormsley (1997)
U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: selection of antibody combinations.Cytometry, 30 5
Raul Braylan, Alberto Orfao, Michael Borowitz, Bruce Davis (2001)
Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting.Cytometry, 46 1
Bruce Davis, Kathy Foucar, Wlodek Szczarkowski, Edward Ball, Tom Witzig, K. Foon, Denise Wells, Pat Kotylo, Rebecca Johnson, Curtis Hanson, David Bessman (1997)
U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: medical indications.Cytometry, 30 5
R. Braylan, M. Borowitz, B. Davis, G. Stelzer, C. Stewart (1997)
U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry. Bethesda, Maryland, November 16-17, 1995.Cytometry, 30 5
Immunophenotyping by flow cytometry has become standard practice in the evaluation and monitoring of patients with hematopoietic neoplasia. However, despite its widespread use, considerable variability continues to exist in the reagents used for evaluation and the format in which results are reported. As part of the 2006 Bethesda Consensus conference, a committee was formed to attempt to define a consensus set of reagents suitable for general use in the diagnosis and monitoring of hematopoietic neoplasms. The committee included laboratory professionals from private, public, and university hospitals as well as large reference laboratories that routinely operate clinical flow cytometry laboratories with an emphasis on lymphoma and leukemia immunophenotyping. A survey of participants successfully identified the cell lineage(s) to be evaluated for each of a variety of specific medical indications and defined a set of consensus reagents suitable for the initial evaluation of each cell lineage. Elements to be included in the reporting of clinical flow cytometric results for leukemia and lymphoma evaluation were also refined and are comprehensively listed. The 2006 Bethesda Consensus conference represents the first successful attempt to define a set of consensus reagents suitable for the initial evaluation of hematopoietic neoplasia. © 2007 Clinical Cytometry Society
Cytometry Part B – Wiley
Published: Jan 1, 2007
Keywords: flow cytometry; reagents; reporting; consensus; optimal
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.